171 related articles for article (PubMed ID: 18975059)
1. Pharmacokinetic and pharmacodynamic modeling of a humanized anti-IL-13 antibody in naive and Ascaris-challenged cynomolgus monkeys.
Vugmeyster Y; Tian X; Szklut P; Kasaian M; Xu X
Pharm Res; 2009 Feb; 26(2):306-15. PubMed ID: 18975059
[TBL] [Abstract][Full Text] [Related]
2. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms.
Vugmeyster Y; Szklut P; Tchistiakova L; Abraham W; Kasaian M; Xu X
Int Immunopharmacol; 2008 Mar; 8(3):477-83. PubMed ID: 18279802
[TBL] [Abstract][Full Text] [Related]
3. Correlation of pharmacodynamic activity, pharmacokinetics, and anti-product antibody responses to anti-IL-21R antibody therapeutics following IV administration to cynomolgus monkeys.
Vugmeyster Y; Allen S; Szklut P; Bree A; Ryan M; Ma M; Spaulding V; Young D; Guay H; Bloom L; Leach MW; O'Toole M; Adkins K
J Transl Med; 2010 Apr; 8():41. PubMed ID: 20420683
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-13 neutralization by two distinct receptor blocking mechanisms reduces immunoglobulin E responses and lung inflammation in cynomolgus monkeys.
Kasaian MT; Tan XY; Jin M; Fitz L; Marquette K; Wood N; Cook TA; Lee J; Widom A; Agostinelli R; Bree A; Schlerman FJ; Olland S; Wadanoli M; Sypek J; Gill D; Goldman SJ; Tchistiakova L
J Pharmacol Exp Ther; 2008 Jun; 325(3):882-92. PubMed ID: 18337474
[TBL] [Abstract][Full Text] [Related]
5. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys.
Bree A; Schlerman FJ; Wadanoli M; Tchistiakova L; Marquette K; Tan XY; Jacobson BA; Widom A; Cook TA; Wood N; Vunnum S; Krykbaev R; Xu X; Donaldson DD; Goldman SJ; Sypek J; Kasaian MT
J Allergy Clin Immunol; 2007 May; 119(5):1251-7. PubMed ID: 17379289
[TBL] [Abstract][Full Text] [Related]
6. Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.
Hart TK; Cook RM; Zia-Amirhosseini P; Minthorn E; Sellers TS; Maleeff BE; Eustis S; Schwartz LW; Tsui P; Appelbaum ER; Martin EC; Bugelski PJ; Herzyk DJ
J Allergy Clin Immunol; 2001 Aug; 108(2):250-7. PubMed ID: 11496242
[TBL] [Abstract][Full Text] [Related]
7. Preclinical safety and pharmacology of an anti-human interleukin-13 monoclonal antibody in normal macaques and in macaques with allergic asthma.
Martin PL; Fisher D; Glass W; O'Neil K; Das A; Martin EC; Li L
Int J Toxicol; 2008; 27(5):351-8. PubMed ID: 19037805
[TBL] [Abstract][Full Text] [Related]
8. Inhaled vs subcutaneous effects of a dual IL-4/IL-13 antagonist in a monkey model of asthma.
Tomkinson A; Tepper J; Morton M; Bowden A; Stevens L; Harris P; Lindell D; Fitch N; Gundel R; Getz EB
Allergy; 2010 Jan; 65(1):69-77. PubMed ID: 19796211
[TBL] [Abstract][Full Text] [Related]
9. Effects of an antibody to interleukin-5 in a monkey model of asthma.
Mauser PJ; Pitman AM; Fernandez X; Foran SK; Adams GK; Kreutner W; Egan RW; Chapman RW
Am J Respir Crit Care Med; 1995 Aug; 152(2):467-72. PubMed ID: 7633694
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic pharmacokinetic/target engagement/pharmacodynamic (PK/TE/PD) modeling in deciphering interplay between a monoclonal antibody and its soluble target in cynomolgus monkeys.
Wang W; Wang X; Doddareddy R; Fink D; McIntosh T; Davis HM; Zhou H
AAPS J; 2014 Jan; 16(1):129-39. PubMed ID: 24287601
[TBL] [Abstract][Full Text] [Related]
11. Death receptor 5 agonistic antibody PRO95780: preclinical pharmacokinetics and concentration-effect relationship support clinical dose and regimen selection.
Xiang H; Reyes AE; Eppler S; Kelley S; Damico-Beyer LA
Cancer Chemother Pharmacol; 2013 Aug; 72(2):405-15. PubMed ID: 23771513
[TBL] [Abstract][Full Text] [Related]
12. A mechanistic PK/PD model for two anti-IL13 antibodies explains the difference in total IL-13 accumulation observed in clinical studies.
Tiwari A; Kasaian M; Heatherington AC; Jones HM; Hua F
MAbs; 2016 Jul; 8(5):983-90. PubMed ID: 27049478
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of an Inhaled IL-13 Antibody Fragment in a Model of Chronic Asthma.
Lightwood D; Tservistas M; Zehentleitner M; Sarkar K; Turner A; Bracher M; Smith B; Lamour S; Bourne T; Shaw S; Gozzard N; Palframan RT
Am J Respir Crit Care Med; 2018 Sep; 198(5):610-619. PubMed ID: 29883204
[TBL] [Abstract][Full Text] [Related]
14. In vitro potency, pharmacokinetic profiles, and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus.
Vugmeyster Y; Guay H; Szklut P; Qian MD; Jin M; Widom A; Spaulding V; Bennett F; Lowe L; Andreyeva T; Lowe D; Lane S; Thom G; Valge-Archer V; Gill D; Young D; Bloom L
MAbs; 2010; 2(3):335-46. PubMed ID: 20424514
[TBL] [Abstract][Full Text] [Related]
15. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma.
Hart TK; Blackburn MN; Brigham-Burke M; Dede K; Al-Mahdi N; Zia-Amirhosseini P; Cook RM
Clin Exp Immunol; 2002 Oct; 130(1):93-100. PubMed ID: 12296858
[TBL] [Abstract][Full Text] [Related]
16. Nebulized anti-IL-13 monoclonal antibody Fab' fragment reduces allergen-induced asthma.
Hacha J; Tomlinson K; Maertens L; Paulissen G; Rocks N; Foidart JM; Noel A; Palframan R; Gueders M; Cataldo DD
Am J Respir Cell Mol Biol; 2012 Nov; 47(5):709-17. PubMed ID: 22904197
[TBL] [Abstract][Full Text] [Related]
17. Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys.
Dudal S; Subramanian K; Flandre T; Law WS; Lowe PJ; Skerjanec A; Genin JC; Duval M; Piequet A; Cordier A; Jarai G; Van Heeke G; Taplin S; Krantz C; Jones S; Warren AP; Brennan FR; Sims J; Lloyd P
MAbs; 2015; 7(5):829-37. PubMed ID: 26230385
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of SB-240563, a humanized monoclonal antibody directed to human interleukin-5, in monkeys.
Zia-Amirhosseini P; Minthorn E; Benincosa LJ; Hart TK; Hottenstein CS; Tobia LA; Davis CB
J Pharmacol Exp Ther; 1999 Dec; 291(3):1060-7. PubMed ID: 10565825
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of IL-13 neutralization in a sheep model of experimental asthma.
Kasaian MT; Donaldson DD; Tchistiakova L; Marquette K; Tan XY; Ahmed A; Jacobson BA; Widom A; Cook TA; Xu X; Barry AB; Goldman SJ; Abraham WM
Am J Respir Cell Mol Biol; 2007 Mar; 36(3):368-76. PubMed ID: 17023688
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.
Xin Y; Xiang H; Jin D; Theil FP; Joshi A; Damico-Beyer LA; Bai S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):217-26. PubMed ID: 22382554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
